Cargando…

Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer

Breast cancer is the second leading cause of cancer death among women. Human epidermal receptor 2 (HER2) positive breast cancer (HER2+ BC) is the most aggressive subtype of breast cancer, with poor prognosis and a high rate of recurrence. About one third of breast cancer is HER2+ BC with significant...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Quanxia, Meng, Ziyuan, Yu, Yuanyuan, Jiang, Feng, Guan, Daogang, Liang, Chao, Zhou, Junwei, Lu, Aiping, Zhang, Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187895/
https://www.ncbi.nlm.nih.gov/pubmed/27983617
http://dx.doi.org/10.3390/ijms17122095
_version_ 1782486922109648896
author Lv, Quanxia
Meng, Ziyuan
Yu, Yuanyuan
Jiang, Feng
Guan, Daogang
Liang, Chao
Zhou, Junwei
Lu, Aiping
Zhang, Ge
author_facet Lv, Quanxia
Meng, Ziyuan
Yu, Yuanyuan
Jiang, Feng
Guan, Daogang
Liang, Chao
Zhou, Junwei
Lu, Aiping
Zhang, Ge
author_sort Lv, Quanxia
collection PubMed
description Breast cancer is the second leading cause of cancer death among women. Human epidermal receptor 2 (HER2) positive breast cancer (HER2+ BC) is the most aggressive subtype of breast cancer, with poor prognosis and a high rate of recurrence. About one third of breast cancer is HER2+ BC with significantly high expression level of HER2 protein compared to other subtypes. Therefore, HER2 is an important biomarker and an ideal target for developing therapeutic strategies for the treatment HER2+ BC. In this review, HER2 structure and physiological and pathological roles in HER2+ BC are discussed. Two diagnostic tests, immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH), for evaluating HER2 expression levels are briefly introduced. The current mainstay targeted therapies for HER2+ BC include monoclonal antibodies, small molecule tyrosine kinase inhibitors, antibody–drug conjugates (ADC) and other emerging anti-HER2 agents. In clinical practice, combination therapies are commonly adopted in order to achieve synergistic drug response. This review will help to better understand the molecular mechanism of HER2+ BC and further facilitate the development of more effective therapeutic strategies against HER2+ BC.
format Online
Article
Text
id pubmed-5187895
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-51878952016-12-30 Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer Lv, Quanxia Meng, Ziyuan Yu, Yuanyuan Jiang, Feng Guan, Daogang Liang, Chao Zhou, Junwei Lu, Aiping Zhang, Ge Int J Mol Sci Review Breast cancer is the second leading cause of cancer death among women. Human epidermal receptor 2 (HER2) positive breast cancer (HER2+ BC) is the most aggressive subtype of breast cancer, with poor prognosis and a high rate of recurrence. About one third of breast cancer is HER2+ BC with significantly high expression level of HER2 protein compared to other subtypes. Therefore, HER2 is an important biomarker and an ideal target for developing therapeutic strategies for the treatment HER2+ BC. In this review, HER2 structure and physiological and pathological roles in HER2+ BC are discussed. Two diagnostic tests, immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH), for evaluating HER2 expression levels are briefly introduced. The current mainstay targeted therapies for HER2+ BC include monoclonal antibodies, small molecule tyrosine kinase inhibitors, antibody–drug conjugates (ADC) and other emerging anti-HER2 agents. In clinical practice, combination therapies are commonly adopted in order to achieve synergistic drug response. This review will help to better understand the molecular mechanism of HER2+ BC and further facilitate the development of more effective therapeutic strategies against HER2+ BC. MDPI 2016-12-14 /pmc/articles/PMC5187895/ /pubmed/27983617 http://dx.doi.org/10.3390/ijms17122095 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lv, Quanxia
Meng, Ziyuan
Yu, Yuanyuan
Jiang, Feng
Guan, Daogang
Liang, Chao
Zhou, Junwei
Lu, Aiping
Zhang, Ge
Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer
title Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer
title_full Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer
title_fullStr Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer
title_full_unstemmed Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer
title_short Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer
title_sort molecular mechanisms and translational therapies for human epidermal receptor 2 positive breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187895/
https://www.ncbi.nlm.nih.gov/pubmed/27983617
http://dx.doi.org/10.3390/ijms17122095
work_keys_str_mv AT lvquanxia molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer
AT mengziyuan molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer
AT yuyuanyuan molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer
AT jiangfeng molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer
AT guandaogang molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer
AT liangchao molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer
AT zhoujunwei molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer
AT luaiping molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer
AT zhangge molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer